BURLINGTON, Mass., July 03, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that
it will hold an Investor and Analyst Day on Monday, July 10, 2017. Flexion executives will discuss plans for commercializing
Zilretta™ (FX006), the company’s lead investigational product candidate for the treatment of osteoarthritis knee pain. Management
will also provide an update on the company’s pipeline, and they will be joined by two medical experts who will present important
clinical perspectives on Zilretta.
Event Details
Date: Monday, July 10, 2017
Time: 10:00 a.m. – 12:00 p.m. EDT
The presentation will be accessible via live webcast at: http://edge.media-server.com/m/p/a5pnvdm8. A replay will also be available on the company’s
website.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the
treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate,
Zilretta, is being investigated for its potential to provide improved analgesia for the millions of U.S. patients who receive
intra-articular injections for OA related knee pain annually.
Corporate Contact: Scott Young Sr. Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 syoung@flexiontherapeutics.com
